Semaglutide

Mechanism

Semaglutide is a modified GLP-1 analog with 94% homology to native GLP-1. A C-18 fatty diacid chain enables albumin binding, extending its half-life to approximately 7 days. It activates the GLP-1 receptor in the hypothalamus and brainstem to modulate satiety signaling and food intake behavior, modulates gastric emptying kinetics, and enhances glucose-dependent insulin secretion from pancreatic beta cells. The compound also modulates glucagon secretion during hyperglycemia. These combined mechanisms produce sustained effects on metabolic signaling pathways and glycemic regulation.

What the literature has looked at

• Studies have investigated GLP-1 receptor-mediated effects on metabolic signaling pathways
• Research has examined cardiovascular biomarker outcomes associated with incretin receptor pharmacology
• Studies have explored effects on hepatic lipid metabolism and steatosis markers
• Research has investigated neurological signaling effects including potential neuroprotective pathways

Research context, not a claim about what this compound does. Research Use Only — not for human or animal consumption. 21+.

Cited work

• Wilding JPH, et al. Once-weekly semaglutide in adults with overweight or obesity. N Engl J Med. 2021;384(11):989-1002.

  Research investigated GLP-1 receptor-mediated effects on metabolic signaling pathways in a large-scale study, examining the relationship between incretin receptor activation and downstream metabolic parameters.

• Lincoff AM, et al. Semaglutide and cardiovascular outcomes in obesity without diabetes. N Engl J Med. 2023;389(24):2221-2232.

  Research examined the relationship between GLP-1 receptor activation and cardiovascular signaling pathways, investigating potential cardioprotective mechanisms beyond direct metabolic effects.

Properties

cas Number

910463-68-2

type

Peptide (GLP-1 analog)